Loading...
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Ledermann, J Embleton, A Raja, F Perren, T Jayson, Gordon C Rustin, G Kaye, S Hirte, H Eisenhauer, E Vaughan, M
Ledermann, J
Embleton, A
Raja, F
Perren, T
Jayson, Gordon C
Rustin, G
Kaye, S
Hirte, H
Eisenhauer, E
Vaughan, M
Citations
Altmetric:
Abstract
Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1-3 inhibitor that has shown antitumour activity in recurrent ovarian cancer. We assessed efficacy and safety of cediranib in combination with platinum-based chemotherapy and as continued maintenance treatment in patients with first relapse of platinum-sensitive ovarian cancer.
Description
Date
2016-03-12
Publisher
Collections
Keywords
Type
Article
Citation
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. 2016, 387 (10023):1066-74 Lancet